HNF4A and hepatocellular carcinoma: In contrast, aberrant β-catenin activation occurs in subsets of HCC, as evidenced by GS+ tumors in patients and in mouse lesions positive for Tcf/Lef1 transcription factor promoter activity (Figure 1B).